Survival in Pulmonary Arterial Hypertension (PAH) for 669 Patients Treated with Selexipag in Clinical Practice: Insights from EXPOSURE
Purpose: Evaluating treatment effect on survival in PAH is challenging. The rare and progressive nature of PAH precludes powered evaluation and, as treatment choice is not random, raw comparisons can lead to misinterpretation. With more than 2000 patients, EXPOSURE has sufficient power to perform a comparative analysis by applying propensity score methods, between treatment with selexipag vs other PAH therapy.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: , P. Escribano Subias, C. O'Donovan, A. Muller, M. Fontana, T.J. Lange, S. Gaine Source Type: research
More News: Cardiology | Heart | Heart Transplant | Hypertension | Lung Transplant | Transplant Surgery | Transplants